Previous close | 17.87 |
Open | 17.90 |
Bid | 17.98 x 900 |
Ask | 18.00 x 800 |
Day's range | 17.81 - 18.24 |
52-week range | 10.84 - 24.79 |
Volume | |
Avg. volume | 2,385,416 |
Market cap | 4.577B |
Beta (5Y monthly) | 0.79 |
PE ratio (TTM) | 4.49 |
EPS (TTM) | 3.99 |
Earnings date | 02 May 2024 |
Forward dividend & yield | 1.12 (6.27%) |
Ex-dividend date | 23 Feb 2024 |
1y target est | 21.50 |
JERSEY CITY, N.J., April 08, 2024--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
SHANGHAI, China & JERSEY CITY, N.J., April 08, 2024--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoint
On International Women's Day, Organon Canada, a subsidiary of Organon (NYSE: OGN), a global healthcare company with a focus on women's health, launches HER Professional Journey and is encouraging businesses in Canada to Invest in HER and address the unique health experiences that women face, including in the workplace, so that women can feel supported and empowered at every stage of their career.